AstraZeneca PLC (LON:AZN)
London · Delayed Price · Currency is GBP · Price in GBX | Market Cap | 184.20B -1.7% |
| Revenue (ttm) | 46.25B +8.6% |
| Net Income | 7.87B +25.9% |
| EPS | 5.03 +25.8% |
| Shares Out | 1.55B |
| PE Ratio | 23.59 |
| Forward PE | 14.84 |
| Dividend | 2.39 (2.00%) |
| Ex-Dividend Date | Aug 6, 2026 |
| Volume | n/a |
| Open | 11,958 |
| Previous Close | 12,042 |
| Day's Range | 11,852 - 12,122 |
| 52-Week Range | 10,524 - 15,732 |
| Beta | 0.20 |
| Analysts | Buy |
| Price Target | 15,746.06 (+32.59%) |
| Earnings Date | Oct 30, 2026 |
About AstraZeneca
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splendil, Munobal, Flodil, Tenormin, Tenormine, Prenormine, Atenol, Zestril, Brilinta/Brilique, Komboglyze, Qtern, Wainua, Byetta, Lokelma, Seloken ZOK, Topr... [Read more]
Financial Performance
In 2025, AstraZeneca's revenue was $58.74 billion, an increase of 8.63% compared to the previous year's $54.07 billion. Earnings were $10.23 billion, an increase of 45.34%.
Financial numbers in USD Financial StatementsAnalyst Summary
According to 24 analysts, the average rating for AZN stock is "Buy." The 12-month stock price target is 15,746p, which is an increase of 32.59% from the latest price.
News
AstraZeneca initiated with an Outperform at RBC Capital
RBC Capital initiated coverage of AstraZeneca (AZN) with an Outperform rating and 14,500 GBp price target The firm believes AstraZeneca offers the most compelling risk/reward in European Union pharma....
AstraZeneca Transcript: Investor update
Tozorakimab demonstrated significant reductions in COPD exacerbations across all patient subgroups, supporting its potential as a first-in-class biologic for a broad population. With FDA priority review and a projected peak sales exceeding $5 billion, it is positioned to address a large unmet need and drive long-term growth alongside a robust pipeline.
AstraZeneca Slides: Investor update
AstraZeneca has posted slides in relation to its latest quarterly earnings report, which was published on September 8, 2026.
AstraZeneca Says Lung-Disease Drug Shows Benefits Across Patient Groups
AstraZeneca said its new drug for COPD showed benefits across a broad patient population in late-stage clinical trials, boosting a medicine the company expects to generate multibillion-dollar sales.
Amgen, AstraZeneca report Phase 3 DeLLphi-305 study met primary endpoint
Amgen (AMGN) announced results from the Phase 3 DeLLphi-305 study, which met its primary endpoint at a pre-specified interim analysis, demonstrating a statistically significant and clinically meaningf...
AstraZeneca's cancer drug combo hits main survival goal in late-stage trial
AstraZeneca said on Tuesday its cancer drug Imfinzi combined with Amgen's targeted immunotherapy Imdelltra significantly improved overall survival in first-line extensive-stage small cell l...
AstraZeneca announces results from Phase III trial of IMFINZI, tarlatamab
Positive high-level results from a planned interim analysis of the DeLLphi-305 Phase III trial showed IMFINZI plus Amgen’s (AMGN) tarlatamab demonstrated a statistically significant and highly clinica...
AstraZeneca says tozorakimab demonstrates reduction in COPD exacerbations
Full results from the Phase III OBERON and TITANIA trials showed that tozorakimab is the first biologic to demonstrate statistically significant and highly clinically meaningful efficacy in reducing m...
Tozorakimab demonstrated statistically significant and highly clinically meaningful reduction in COPD exacerbations in OBERON and TITANIA Phase III trials
WILMINGTON, Del.--(BUSINESS WIRE)--Full results from the positive Phase III OBERON and TITANIA trials showed that tozorakimab is the first biologic to demonstrate statistically significant and highly ...
AstraZeneca's COPD drug scores two late-stage trial wins as full data boosts blockbuster hopes
AstraZeneca released full results from two successful late-stage trials on its experimental drug for chronic obstructive pulmonary disease. The detailed data reinforces hopes that the product could be...
AZN Looks 10.4% Undervalued on GF Value⢠as Dividend Sustainability Shines
AZN Looks 10.4% Undervalued on GF Value⢠as Dividend Sustainability Shines
ETCAMAH (camizestrant) in combination with a CDK4/6 inhibitor approved in the US for 1st-line advanced HR-positive breast cancer
AstraZeneca’s ETCAMAH (camizestrant) in combination with a cyclin-dependent kinase (CDK) 4/6 inhibitor (abemaciclib, palbociclib or ribociclib) has been approved in the US for the treatment of adult p...
Guardant Health Announces Landmark FDA Approval of Guardant360 CDx as Companion Diagnostic for AstraZeneca’s ETCAMAH (camizestrant) in Advanced Breast Cancer
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that the U.S. Food and Drug Administration (FDA) has approved Guardant360 CDx as a companion diagnostic (CDx) ...
Weekly Buzz: IONS, MIST, BIIB, AZN Win Nods; TCRX, NVS Cut Jobs; OVID, VIR Data; REGN, PASG Deals
(RTTNews) - This week's biotech roundup saw a flurry of FDA and EU approvals across neurology, oncology, cardiology, and rare diseases, alongside new partnerships, trial readouts, and restructuring mo...
AZN Looks 9.4% Undervalued on GF Value⢠Amid Strong Dividend Profile
AZN Looks 9.4% Undervalued on GF Value⢠Amid Strong Dividend Profile
AstraZeneca gets orphan designation for treatment of hepatocellular carcinoma
AstraZeneca (AZN) Pharmaceuticals was granted FDA orphan designation for a treatment of hepatocellular carcinoma, according to a post to the agency’s website.
C4X Discovery Holdings PLC: C4X Discovery to receive milestone payment for NRF2 exclusive worldwide license agreement
4 September 2026 - C4X Discovery Holdings Ltd ("C4XD"), a pioneering Drug Discovery company, today announces that it will receive a $13 million milestone payment from AstraZeneca [LON: AZN], trigg...
The Zacks Analyst Blog Highlights AMD, Costco, AstraZeneca, Peoples Bancorp of North Carolina and Spruce Power
AMD, Costco and AstraZeneca headline Zacks' latest research, with AI demand, membership strength and new drugs shaping their outlooks.
Top Stock Reports for AMD, Costco & AstraZeneca
AMD, Costco and AstraZeneca headline today's stock reports, with AI demand, membership growth and drug pipelines shaping their outlooks.
AZN Looks 10.6% Undervalued on GF Value⢠as Dividend Remains Sustainable
AZN Looks 10.6% Undervalued on GF Value⢠as Dividend Remains Sustainable
AstraZeneca's $80 Billion Plan Gets Another Tagrisso Win
AstraZeneca's $80 Billion Plan Gets Another Tagrisso Win
AZN Looks 10.5% Undervalued on GF Value⢠as Dividend Remains Secure
AZN Looks 10.5% Undervalued on GF Value⢠as Dividend Remains Secure
AZN Looks 10.5% Undervalued on GF Value⢠as Dividend Remains Attractive
AZN Looks 10.5% Undervalued on GF Value⢠as Dividend Remains Attractive
AZN Looks 10.5% Undervalued on GF Value⢠Amid Solid Dividend Fundamentals
AZN Looks 10.5% Undervalued on GF Value⢠Amid Solid Dividend Fundamentals
AstraZeneca completes global license agreement for Zegfrovy in lung cancer
AstraZeneca (AZN) announced the completion of the exclusive license agreement with Dizal Pharmaceutical for Zegfrovy – sunvozertinib -, an oral irreversible epidermal growth factor receptor, or EGFR, ...